Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Valneva

Valneva's Chikungunya Shot Shows Strong, Long-Lasting Antibody Persistence At Three Years, Comparable In Older And Younger Adults

Valneva reports long-lasting antibody persistence in its chikungunya vaccine three years post-dose, supporting its global approvals and expansion efforts.

Benzinga

Worst of Westminster: Labour Lords U-turn and interest rates hike

Good evening and welcome to the latest edition of The Worst of Westminster! The week kicked off with MPs voting overwhelmingly to approve the…

The National (Scotland)

Axed Livingston Covid vaccine contract cost taxpayers £358million

The contract was axed by ministers in 2021

Daily Record

From analysis to the latest developments in health,
read the most diverse news in one place.

Axed Livingston Covid vaccine contract cost taxpayers £358million

French firm Valneva was supposed to manufacture more than 100 million vaccines at its site in Livingston but the contract was axed by ministers in 2021.

Daily Record

Axed Covid vaccine deal with Livingston firm cost taxpayers £358m

THE UK Government has been accused of “absolutely shafting” a Scottish vaccine plant after it emerged a contract it axed cost taxpayers £358.6…

The National (Scotland)

Axed Covid vaccine contract cost taxpayers £358 million

French company now considering selling the plant specially built in Livingston to manufacture the vaccines

Insider UK

Axed Covid vaccine contract cost taxpayers £358m

The UK Government pulled out of the deal with French firm Valneva in 2021.

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Vaccine trials against chikungunya virus 'promising', but more research is still needed

Franco-Austrian drugmaker Valneva's vaccine candidate against chikungunya – a mosquito-borne virus that causes occasional outbreaks across the world – has revealed promising results in a wide-ranging new trial.

Radio France Internationale

Valneva Shares Topple As It Hits Ethics Roadblock With Pfizer In Lyme Disease Test

Valneva stock plummeted Friday after Pfizer said it will drop roughly half of the participants enrolled in their Lyme disease vaccine study.

Investors Business Daily

Will A Pfizer-Partnered Vaccine Help Valneva Stock Buck Its Recent Downtrend?

Valneva stock rose Thursday after it said volunteers who received its Pfizer-partnered Lyme disease shot still had antibodies after six months.

Investors Business Daily

EU watchdog backs Sanofi Covid booster jab

The Hague (AFP) - The EU on Thursday approved a Covid booster vaccine by French drug maker Sanofi and Britain's GSK after it gave positive results against the Omicron variant in trials.

AFP

Why O2Micro International Is Trading Higher By 7%; Here Are 25 Stocks Moving Premarket

Gainers

Benzinga

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ:KRYS) Biologics License Application (BLA) for its lead candidate B-VEC in the treatment of patients with dystrophic epidermolysis bullosa (DEB). The regulatory agency has granted Priority Review designation and assigned a target actin date of February 17,…

Benzinga

WHO recommends Valneva's COVID vaccine

The World Health Organization (WHO) on Thursday recommended the use of French drugmaker Valneva's COVID-19 vaccine.

Reuters

Get all your
news in one place.

100’s of premium titles.
One news app.

WEKU

A vaccine for Lyme disease is in its final clinical trial

There isn't currently a Lyme disease vaccine on the U.S. market. Researchers are hoping to change that.

Benzinga

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful

Here's a roundup of top developments in the biotech space over the last 24 hours:

Axios

Trial seeks to develop first Lyme disease vaccine in 2 decades

The only Lyme disease vaccine previously marketed in the U.S. was discontinued in 2002.

The Independent UK

Major test of first possible Lyme vaccine in 20 years begins

Researchers are seeking thousands of volunteers in the U.S. and Europe to test the first potential vaccine against Lyme disease in 20 years

Get all your
news in one place.

100’s of premium titles.
One news app.

Reuters

Climate change puts Lyme disease in focus for France's Valneva after COVID blow

With climate change spurring more cases of tick-borne Lyme disease, drugmaker Valneva is betting big on a vaccine as it looks beyond disappointing sales of its COVID shot.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022

Reuters

EU drops nearly all of its order for Valneva COVID vaccine

The European Commission has dropped nearly all of its order of 60 million doses of a new COVID-19 vaccine from French firm Valneva, the EU executive said on Wednesday, in a move that all but wipes out the shot's value for the company. The EU agreed in November last year…

The Independent UK

EU regulator authorizes COVID shot made by France's Valneva

The European Medicines Agency says it is recommending the authorization of the coronavirus vaccine made by French pharmaceutical Valneva, making it the sixth shot to be given the green light in Europe

StockNews.com

Pfizer Strikes Deal With French Vaccine Maker -- Buy Or Sell?

Pharmaceutical company Pfizer (PFE) reported impressive first-quarter financials and is well-positioned to benefit from the equity subscription agreement with French vaccine maker Valneva. However, given the growing economic uncertainty, would it be worth adding the stock to your portfolio? Read more to find out.

Benzinga

Why Shares Of Valneva SE Are Soaring Today

Valneva SE (NASDAQ: VALN) shares are trading higher after the company and Pfizer announced they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and License Agreement for Lyme disease vaccine candidate VLA15.

Investors Business Daily

Valneva Nearly Doubles After Pfizer Invests $95 Million For A Hefty Stake

Valneva stock rocketed Tuesday on a $95 million investment from Pfizer, its Lyme disease vaccine partner. Pfizer will get an 8.1% stake.

1 2 3

People

Mangeet Kaur BounsMangeet

595 stories

Hannah Bardell

47 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

World Health Organization

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.